$9.63 0.29 (+3.10%)
11/25/2009 4:00 PM

Seattle Genetics, Inc. (SGEN)

CAPS Rating: 4 out of 5

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.

Featured Broker Partners